Search
SUVN-502
go.drugbank.com/drugs/DB06140InvestigationalSUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSulfadimethoxine
go.drugbank.com/drugs/DB06150ApprovedVet approvedWithdrawnIt is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies. … Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections.
Synonyms: N(1)-(2,6-Dimethoxy-4-pyrimidinyl)sulfanilamide, 4-amino-N-(2,6-dimethoxy-4-pyrimidinyl)benzenesulfonamideMixtures: TP-SULTRIME 80/400MG/G POWDERForodesine
go.drugbank.com/drugs/DB06185Investigationalleukemia and cutaneous T-cell lymphoma. … Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic
Synonyms: 1,4-Dideoxy-4-aza-1-(S)-(9-deazahypoxanthin-9-yl)-D-ribitol, (1S)-1,4-dideoxy-4-imino-(9-deazahypoxanthin-9-yl)-D-ribitolCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingAtrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigationalAtrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsAlogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalAlogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). … Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer.
Mixtures: INCRESINA PCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigationalTapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.
Synonyms: 3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol, PHENOL, 3-((1R,2R)-3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL)-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: REVOLADE® TABLETAS 25 MG, REVOLADE ® TABLETAS 50 MGDoripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawn, resulting in a premature termination of the trial. … Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen.
Categories: Heterocyclic Compounds, 2-RingProducts: DORVAK®, DORIPURE® 500Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalVernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher he...
Synonyms: (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-olCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring